Biggest News Aggregation in the World
๐Ÿ“ฐ Aadi Bioscience News

Page 5 - Aadi Bioscience News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Aadi Bioscience. Real-time updates on events, politics, business and more.

Knott David M Jr Acquires 156,446 Shares of Aadi Bioscience, Inc. (NASDAQ:AADI)

Knott David M Jr lifted its holdings in Aadi Bioscience, Inc. (NASDAQ:AADI – Free Report) by 574.3% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 183,688 shares of the company’s stock after buying an additional 156,446 shares during the period. […]
United States Neil Desai Aadi Bioscience Knott Davidm Jr Barclays Plc Group Plc

A Deep Dive into the Personalized Medicine Market: Strategies for Tailored Health | CAGR 11.2%

The latest research study, titled โ€œGlobal Personalized Medicine Market: Outlook and Forecast 2023-2030,โ€ has been unveiled by Allied Market Research. This comprehensive analysis delves into the marketโ€™s risk assessment, while also illuminating potential opportunities. The study equips stakeholders with invaluable in...
Hong Kong United States United Kingdom David Correa Eli Lilly Aadi Bioscience

Aadi Bioscience (NASDAQ:AADI) Earns "Buy" Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Aadi Bioscience (NASDAQ:AADI – Free Report) in a research report sent to investors on Thursday morning, Marketbeat Ratings reports. HC Wainwright currently has a $45.00 price target on the stock. HC Wainwright also issued estimates for Aadi Bioscience’s FY2024 earnings at ($2.98) EPS. Separately, LADENBURG THALM/SH […]
Neil Desai Aadi Bioscience Royal Bank Barclays Plc Aadi Bioscience Inc Citigroup Inc
Source: wkrb13.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

HC Wainwright Reaffirms Buy Rating for Aadi Bioscience (NASDAQ:AADI)

HC Wainwright restated their buy rating on shares of Aadi Bioscience (NASDAQ:AADI – Free Report) in a research note issued to investors on Thursday, MarketBeat.com reports. They currently have a $45.00 price target on the stock. HC Wainwright also issued estimates for Aadi Bioscience’s FY2024 earnings at ($2.98) EPS. Separately, LADENBURG THALM/SH SH lowered their […]
Aadi Bioscience Neil Desai Jpmorgan Chase Co Aadi Bioscience Inc Blackrock Inc Northern Trust Corp

PEComa Market Review 2019-2022 and Forecast 2023-2032: Industry Assessment, Drugs, Specific Tumor Types, KOL Views, Market Access & Reimbursement

Dublin, Aug. 07, 2023 (GLOBE NEWSWIRE) -- The "PEComa - Market Insights, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The report provides in-depth insights into PEComa, including historical and forecasted epidemiology, market trends, and treatment practices in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. Market Assessment: The report covers current treatment practices, emerging dr...
United States United Kingdom Aadi Bioscience Market Forecast Tumor Types Key Opinion Leaders
Source: yahoo.com

Aadi Bioscience (AADI) Scheduled to Post Quarterly Earnings on Wednesday

Aadi Bioscience (NASDAQ:AADI – Get Free Report) is scheduled to be announcing its earnings results before the market opens on Wednesday, August 9th. Analysts expect the company to announce earnings of ($0.64) per share for the quarter. Aadi Bioscience (NASDAQ:AADI – Get Free Report) last posted its earnings results on Wednesday, May 10th. The company […]
Aadi Bioscience Neil Desai Geode Capital Management Securities Exchange Commission Aadi Bioscience Inc Renaissance Technologies

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science